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Abstract
Background: Release of virus-blocking Wolbachia-infected mosquitoes is an emerging disease control strategy that
aims to control dengue and other arboviral infections. Early entomological data and modelling analyses have
suggested promising outcomes, and wMel Wolbachia releases are now ongoing or planned in 12 countries. To help
inform government, donor, or philanthropist decisions on scale-up beyond single city releases, we assessed this
technology’s cost-effectiveness under alternative programmatic options.
Methods: Using costing data from existing Wolbachia releases, previous dynamic model-based estimates of
Wolbachia effectiveness, and a spatially explicit model of release and surveillance requirements, we predicted the
costs and effectiveness of the ongoing programme in Yogyakarta City and three new hypothetical programmes in
Yogyakarta Special Autonomous Region, Jakarta, and Bali.
Results: We predicted Wolbachia to be a highly cost-effective intervention when deployed in high-density urban
areas with gross cost-effectiveness below $1500 per DALY averted. When offsets from the health system and
societal perspective were included, such programmes even became cost saving over 10-year time horizons with
favourable benefit-cost ratios of 1.35 to 3.40. Sequencing Wolbachia releases over 10 years could reduce
programme costs by approximately 38% compared to simultaneous releases everywhere, but also delays the
benefits. Even if unexpected challenges occurred during deployment, such as emergence of resistance in the
medium-term or low effective coverage, Wolbachia would remain a cost-saving intervention.
Conclusions: Wolbachia releases in high-density urban areas are expected to be highly cost-effective and could
potentially be the first cost-saving intervention for dengue. Sites with strong public health infrastructure, fiscal
capacity, and community support should be prioritised.
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Background
The mosquito species Aedes aegypti and Ae. albopictus
are responsible for transmitting a range of growing glo-
bal arboviral infections. Existing vector control tools
alone have been unable to sustainably control these
mosquito species or the diseases they transmit [1], and a
range of novel technologies are under development [2].
One such novel intervention is the release of mosqui-
toes infected with the intracellular bacterium Wolbachia
[3]. Mosquitoes infected with Wolbachia (i) are less
likely to disseminate dengue, chikungunya, Zika, and yel-
low fever viruses and thus are less likely to become in-
fectious [3–5] and (ii) can suppress or replace the
natural mosquito population due to fatal cytoplasmic in-
compatibility among Wolbachia wild-type mating pairs
[3]. Wolbachia can, therefore, be used to either replace
the existing mosquito population with a lower compe-
tence phenotype by releasing females or suppress exist-
ing population by releasing males. To date, 13 countries
have ongoing replacement programmes at various stages
of development, with 12 through the World Mosquito
Programme (WMP [6]) and an independent programme
in Malaysia [7]. Meanwhile, China (with Ae. albopictus)
[8], Singapore [9], and the USA [10] have chosen to use
suppression-based programmes due to perceived greater
compatibility with their existing intensive and long-term
efforts to suppress mosquito populations.
Replacement programmes with Wolbachia entail sub-
stantial initial investments to establish Wolbachia in the
mosquito population through intensive releases at the
beginning of the programme but potentially offer con-
siderable long-term benefits. The replacement approach
contrasts with suppression strategies with Wolbachia,
sterile insect techniques, or conventional vector control
tools, which likely need ongoing application. Both ap-
proaches are in the early stages of gathering entomo-
logical and epidemiological evidence of effectiveness [2].
Among these novel methods, replacement with wMel
Wolbachia has, arguably, the most developed evidence
base so far [11] because it has demonstrated replacement
in multiple sites [12, 13], durability of unaltered replace-
ment since 2011 and cessation of autochtonous trans-
mission in northern Australia [14, 15], reductions in
reported dengue cases in observational study designs in
five countries [16], and a cluster randomised trial is cur-
rently underway in Yogyakarta, Indonesia [17, 18], with
epidemiological outcome results expected in late 2020.
Recent events including the 2015–2017 Latin Ameri-
can Zika outbreak and the record-breaking 2019 global
dengue outbreak have hastened the adoption of novel
Aedes control tools. Given the acute need to make deci-
sions on adoption, mathematical models can be used to
predict impact in different areas long before field data
become available [19, 20]. Pairing these epidemiological
predictions with intervention cost and cost-of-illness
data enables cost-effectiveness calculations that can in-
form decisions on Wolbachia scale-up.
One such priority setting is Indonesia, where city-wide
Wolbachia releases are already planned in Yogyakarta
City after the randomised trial [17]. In 2016, Indonesia
launched its “Healthy Indonesia Program with Family
Approach”, which includes cleaning the environment
and addressing communicable diseases, including mal-
aria and dengue [21]. This programme provides encour-
agement and some national funding. In addition, in the
Yogyakarta Special Autonomous Region (SAR), the gov-
ernor has confirmed his support for novel technologies,
including Wolbachia [22], suggesting support for expan-
sion beyond Yogyakarta City.
Cost-effectiveness analyses (CEAs) have proved instru-
mental for the early adoption of a number of interven-
tions, including for Aedes-borne pathogens. Fitzpatrick
et al. estimated that, assuming they were 70–90% effect-
ive, conventional Aedes suppression tools would achieve
cost-effectiveness between $679 and $1331 per
disability-adjusted life year (DALY) averted (2013 USD)
[23]. The recently developed dengue vaccine, Deng-
vaxia®, also included model-predicted CEA as part of its
feasibility assessment, with predictions without sero-
testing of $11–44 per DALY averted (2014 USD) [24].
Dengvaxia® has also been estimated to be highly cost-
effective ($1800 per DALY, health systems perspective)
or cost saving ($-1800 per DALY, societal perspective)
under the WHO’s modified individual test-and-vaccinate
recommendation, however with more limited overall im-
pact (14.3% reduction in hospitalisation) [25].
Here we use the existing Wolbachia release cost and
programme data to build a model that predicts the cost
of release in different environments. Using a dynamic
simulation model, we synthesise cost predictions with
previously published estimates of Wolbachia effective-
ness [19] to assess cost-effectiveness. We then assess the
sensitivity of predicted cost-effectiveness to alternative
programmatic options for government or private funders
to consider the next stage of scale-up of this technology.
Methods
Phases of the programme
In this analysis, we conceptually divide a potential Wol-
bachia replacement programme in a given city into four
phases based on previous WMP operations. We do not
consider the additional costs of obtaining regulatory ap-
proval in Indonesia as Wolbachia release has already
been approved by the local Yogyakarta SAR government
and the national government already has an active in-
volvement in the project as part of the independent data
monitoring committee. Phase 1 (“setup”, 2-year dur-
ation) includes establishing insectaries and a mosquito
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colony, laboratories, site offices, local regulatory ap-
proval, hiring staff, baseline entomological surveys (in-
cluding insecticide resistance monitoring), and planning
and administering the programme and pre-release com-
munity engagement. Phase 2 (“release”, 1-year duration)
involves the release of Wolbachia mosquitoes over target
areas applying the resources established during phase 1.
In phase 3 (“short-term monitoring”, 3-year duration),
ongoing surveillance of the mosquito and human popu-
lation is conducted in the release area. Phase 4 (“long-
term monitoring”, 7-year duration) entails reduced ento-
mologic monitoring as the intervention proves its
reliability.
In the existing programme in Yogyakarta City,
programme setup took 4 years [18]; however, this in-
cluded gaining national approval, design of the cluster
randomised trial, all phase 1 activities, and release in half
the city. We anticipate faster setup times of subsequent
programmes elsewhere in Indonesia due to the experi-
ences and approvals gained in Yogyakarta City.
For the main analysis, we consider two speed scenar-
ios: (i) an “accelerated” scenario, with every area con-
ducting phases 1–4 simultaneously and independently
(total programme length 13 years), and (ii) a “sequenced”
scenario, in which phase 2 releases are spread over 10
years with certain centralised resources moved or re-
utilised across different locations (total programme
length 20 years, Additional file 1, S1.1) [13, 19, 26–31].
Costing Wolbachia releases (phases 1 and 2)
We hypothesised that the main determinants of the cost
of releasing Wolbachia per square kilometre (km) were
directly or indirectly related to (i) the human population
density in the release area, (ii) release material (adult or
egg mosquitoes), (iii) local cost of labour (as measured
by country Gross Domestic Product adjusted for Pur-
chasing Power Parity (GDP PPP) [32]), and (iv) phase of
the programme. Previous Wolbachia releases have
shown that higher human density areas require higher
mosquito release numbers per unit area because they
typically have higher natural mosquito population sizes,
hence raising costs [33]. Transportation costs of Wolba-
chia-infected mosquito eggs are lower than for adult re-
leases because they can be distributed in smaller
containers and because the community can undertake
releases; however, this can also increase community en-
gagement costs. Adult releases require specific equip-
ment and personnel to drive around the target area and
conduct releases at pre-specified sites, but can poten-
tially be achieved more quickly.
Data were extracted from WMP budgets for releases
in Indonesia, Colombia, Sri Lanka, Australia, and
Vanuatu (Additional file 1, S1.2). These data were used
to fit a generalised linear regression model between cost
per km2 of release area and the above covariates (Add-
itional file 1, S1.3).
Costing long-term surveillance (phases 3 and 4)
Our estimates of the long-term monitoring costs of a
Wolbachia programme (phases 3 and 4) build on a de-
tailed budget analysis developed by the WMP for phase
2 of the programme in Yogyakarta City (Additional file
1, S1.2). This includes a gradual reduction in monitoring
intensity with corresponding budget reductions (Add-
itional file 1, S1.1).
Modelling effectiveness and cost of dengue illness
averted
Spatially explicit estimates of baseline and averted den-
gue cases were obtained from a recent related study
[19]. In this study, spatially varying estimates of the
current case burden across Indonesia were first esti-
mated using a geospatial model that accounts for the
effects of climate and socioeconomic factors in the
spatial distribution of dengue burden. Within each 5
km × 5 km pixel, a dynamic simulation model then esti-
mated the long-term average force of infection required
to generate the number of estimated cases. Data from la-
boratory vector competence experiments [29] were then
used to estimate the reduction in force of infection likely
to occur if Wolbachia were present in 100% (or 50% for
the sensitivity analysis) of the natural mosquito popula-
tion from the beginning of phase 3 of the programme
(i.e. once all releases have been completed). The dy-
namic simulation model was then used to translate this
force of infection reduction into the number of cases
averted per year once a new steady endemic state has
been reached which also includes indirect or spillover ef-
fects if Wolbachia coverage were less than 100%. DALYs
were calculated based on the average age of dengue
cases and life expectancy at a national level in Indonesia.
We assume that neither the age distribution of cases nor
the costs associated changes as a result of the Wolbachia
programme. Disease severity-specific (but not geograph-
ically varying) cost per case data [34] was then applied
to case totals to estimate the economic costs of dengue
cases and the economic benefits of averting Wolbachia
relative to a baseline scenario of no action. All case
counts and costs were then downscaled to 100 m × 100
m spatial resolution to match the resolution of popula-
tion datasets using bilinear interpolation.
Candidate release sites
In this analysis, we produce estimates for four candidate
sites: (1) Yogyakarta City, (2) remaining areas in
Yogyakarta SAR, (3) most of the special capital region of
Jakarta (excluding Kepulauan Seribu [Thousand Islands]
Regency), and (4) the island of Bali.
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We chose this focus based on a combination of polit-
ical, economic, and epidemiologic considerations. The
Yogyakarta City trial carried an ethical and political ex-
pectation to assess expanding releases across the rest of
Yogyakarta City and the remainder of the SAR. The
other two candidate sites, Jakarta and Bali, are two of
the country’s most important economic regions as com-
mercial and tourism hubs. In epidemiologic terms, high-
density cities, such as Jakarta and Denpasar, Bali, have a
disproportionately high concentration of national den-
gue burden [19] and island-wide releases are likely to
minimise the risk of re-introduction of native Ae. aegypti
populations.
Within each of these sites, not every area is expected
to be covered by Wolbachia. We consider only areas
with a human population density of at least 1000 people
per km2 as eligible for Wolbachia releases. Previous
WMP releases in Townsville and Cairns, Australia, have
proven the ability to establish Wolbachia in areas ap-
proaching 1000 people per km2 (Fig. 1), but based on
existing programme experience, lower population dens-
ities are likely to prove prohibitive to natural mosquito
dispersal and may significantly increase the cost or lower
persistence of Wolbachia mosquitoes.
Time horizon, acquisition of benefits, and discounting
As Wolbachia is an early-stage technology, we take a
conservative approach to our calculation of cost-
effectiveness. We only assume benefits of Wolbachia
persist for 10 years post completion of releases in the
target area (i.e. benefits only accumulated in phases 3–4,
Additional file 1, S1.1) based on the duration of contin-
ued persistence of Wolbachia releases in northern
Queensland since 2011 [35].
We assumed that the number of cases averted would be
the same each year. All costs and benefits are given in
present value 2018 USD and were discounted at 3% per
annum [36], calculated at the end of each year. The cost
of the programme was predicted using population data at
100m × 100m resolution from Worldpop [37] assuming a
programme using egg releases with Indonesia’s national
2018 per capita GDP (PPP, $12,378).
Two measures of cost-effectiveness are shown: first,
from a health systems perspective (gross cost-
Fig. 1 The fitted relationship between human population density and projected cost of deployment of Wolbachia per km2 (a) and cost per
person (b). All axes are on log10 scales. The cost per km
2 model fit mean (solid lines) and standard error (dashed lines) for each programme
phase are shown. Circle area is proportional to the size of the release area in each site
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effectiveness), where the investment cost of the
programme is divided by the number of DALYs averted
over the 10 years post deployment (discounted at 3% per
year); second, from a societal perspective (net cost-
effectiveness), where offsets to direct medical treatment
costs are first deducted from the programme investment
costs. Benefit-cost ratios are also calculated from health
systems and societal perspectives separately. We com-
pared all scenarios against the alternative option of con-
tinuing existing dengue control measures, which primarily
consist of insecticide-based vector control. We did not
cost such interventions and assume that they will continue
in parallel to and independently of the Wolbachia
programme due to their purpose spanning vector control
for a variety of different vector species.
Sensitivity analyses
To assess the sensitivity of our predictions to uncertain-
ties in various inputs to our model, we performed a uni-
variate sensitivity analysis based on the 2.5% and 97.5%
estimates for each of the following parameters: (i) case
burden, (ii) Wolbachia effectiveness, (iii) cost of Wolba-
chia releases, and (iv) cost per episode of dengue illness.
In addition, we also examined the sensitivity of cost-
effectiveness to several hypothesised environmental and
genetic challenges and changes that may occur as a con-
sequence of Wolbachia introduction [38]. These include
(i) low coverage (50% vs baseline 100% coverage), (ii) re-
leases that are initially uncompetitive with wild-type
mosquito populations, and (iii) emergence of resistance
(after 5 years). The cost-effectiveness of programme
modifications to address these challenges is also
assessed. Furthermore, we predict the cost-effectiveness
of future cost-saving adaptations of the programme in-
cluding (iv) reliance on passive disease surveillance (as
opposed to continued entomological surveillance in
phase 4 of the programme) and (v) generic innovations,
efficiencies, and economies of scale that reduce the cost
base of the programme by 50%. Further details on the
rationale for these scenarios and their parameterisation
are available in Additional file 1, S1.4. All analyses were
performed in R version 3.6.1. with all code publicly avail-
able in the following GitHub repository (https://github.
com/obrady/Wolbachia_CE/tree/V1). This manuscript
conforms to the Consolidated Health Economic Evalu-
ation Reporting Standards (CHEERS) checklist which
can be found in Additional file 2.
Results
Wolbachia programme costs
The results of our model to predict the cost of releasing
Wolbachia mosquitoes in new areas using existing
programme budgets are shown in Fig. 1. This model
identified human population density and programme
phase as significant covariates of programme cost per
km2 of release area (p = 0.003 and p = 0.026 respectively,
two-sided t test, Additional file 1, S1.3). Release material
(eggs or adult mosquitoes) or national GDP per capita
(as a proxy for local labour costs) were not found to be
significant (p = 0.98 and 0.31 respectively) but were
retained in the final model due to limited between site
variance. Models with the response variable of cost per
km2 gave superior cost data fit to models with a re-
sponse variable of cost per person, so were used
throughout (Additional file 1, S1.3).
Each of the four candidate sites differs in size and hu-
man population density, comprising a small city
(Yogyakarta City), a large city (Jakarta), and two
moderate-size urban-rural mixes (Yogyakarta SAR and
Bali, Table 1). Because we assume Wolbachia to be suit-
able only in areas with density greater than 1000 people
per km2, only 24.8% and 14.9% of the land area in
Yogyakarta SAR and Bali are eligible for Wolbachia re-
lease, compared to 100% in urban areas, although these
areas do still contain the majority of people (Table 1).
The estimated cost of an accelerated (10-year) Wolba-
chia programme ranges from $5.8 million in Yogyakarta
City to $133.3 million in Jakarta (present value 2018
USD, Table 1). While the urban sites have a smaller re-
lease area than their urban-rural mix counterparts, the
cost per km2 of releasing in high-density areas is much
higher (Fig. 1); however, because more people are cov-
ered, urban areas lead to more favourable cost per per-
son covered (~$12 vs $14–21, Table 1).
Conducting releases over a longer sequenced
programme (total programme length 20 years vs 13 years)
can reduce overall costs by 11–38% (Table 1), but also
delay benefits (Fig. 2). In this analysis, we assume 10 years
of benefits for each area in which Wolbachia mosquitoes
are released because there is currently substantial uncer-
tainty over costs and effectiveness beyond 10 years (Fig. 2).
Should Wolbachia prove more durable than this, acceler-
ated programmes and their quicker acquisition of benefits
would become more preferable relative to sequenced pro-
grammes; however, the challenges of their greater upfront
costs would remain.
Benefits
Combining health systems costs and societal costs (lost
wages due to work absences attributable to sickness and
the value of life lost due to premature death), Indonesia’s
national economic burden of dengue in 2017 has been
estimated at $681.26 million [34], with costs due to hos-
pitalised non-fatal cases (44.7%), fatal cases (44.3%), am-
bulatory non-fatal cases (5.7%), and non-medical cases
(5.3%) [34]. We predict substantial reductions in dengue
case and economic burden in all sites. As estimated in
previous work [19], long-term average percentage
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reductions are likely to be highest in low transmission
intensity environments (87.2% reduction in Yogyakarta
SAR vs 65.7% reduction in Jakarta, Table 2). However,
because Wolbachia programmes can achieve higher
coverage in dense high transmission intensity cities, the
percentage reduction across the whole site area becomes
more favourable (65.7% in Jakarta vs 59.1% in
Yogyakarta SAR and 52.4% in Bali). Medium transmis-
sion intensity high-density cities, such as Yogyakarta
City, are likely to see the highest percentage reduction
and may even see elimination (94.4%, 95% uncertainty
interval [95UI] 36.5–100%).
The annual cost savings of averting these cases are
substantial, ranging from $980,000 (95UI $350,000–$2,
170,000) in Yogyakarta City to $27.1 million (95UI
$10.58–$49.35 million) in Jakarta. As estimated in previ-
ous work [34], these cost savings are divided approxi-
mately equally between medical costs and societal costs.
Table 1 Baseline characteristics and model-predicted release costs for current and future release areas. Prices are in present value
2018 USD. Figures in brackets represent 95% uncertainty intervals. All costs are discounted at 3% per annum. Accel. denotes
accelerated; Seq. denotes sequenced
Existing area Candidate sites
Yogyakarta City Yogyakarta SAR Jakarta Bali
Residents (millions) 0.46 3.24 11.19 4.08
Percentage of people
covered by Wolbachia
100 65.9 100 59.7
Area (km2) 37.24 3666.21 764.48 6476.03
Percentage of area
eligible for Wolbachia
100 24.8 99.9 14.9
Density in covered
area (persons/km2)
12,351 2352 14,647 2532
Total cost
(US$ millions)
Accel. Seq. Accel. Seq. Accel. Seq. Accel.
5.84
(5.81–5.87)
27.41
(27.37–27.45)
30.68
(30.65–30.73)
83.33
(83.22–83.49)
133.30
(133.14–133.49)
34.88
(34.81–34.93)
51.66
(51.57–51.72)
Cost per person covered 12.70
(12.63–12.77)
12.83
(12.81–12.85)
14.36
(14.35–14.38)
7.45
(7.44–7.46)
11.92
(11.90–11.93)
14.32
(14.29–14.34)
21.21
(21.17–21.23)
Fig. 2 Distribution of cumulative costs and savings over time in an accelerated (3 years, left panel) and sequenced (10 years, right panel) roll out
in Yogyakarta City in 2018 USD. Uncertainty represents uncertainty in programme cost and intervention effectiveness beyond the 10-year post-
release time horizon used in this analysis. All costs and benefits are in present-day value 2018 USD discounted at 3% per annum
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Cost-effectiveness
Due to the heterogeneous nature of risk and cost, esti-
mated cost-effectiveness values are spatially variable
(Table 3, Fig. 3). Generally, cost-effectiveness is most
favourable in high-density urban environments with
gross cost-effectiveness (cost of averted disease cases not
included) reaching as favourable as $1100 per DALY
averted in specific places (Fig. 3c), especially in a se-
quenced programme (Table 3). Although the overall
gross cost-effectiveness of the projected programmes in
Yogyakarta SAR and Bali are less favourable than their
urban counterparts (Table 3), there are many sub-areas
within these sites where Wolbachia programmes could
have equally as favourable cost-effectiveness (Fig. 3b, d).
This is most pronounced for the Yogyakarta SAR sce-
nario where the surrounding urban areas of Sleman,
Bantul, and the isolated towns of Sentol and Wonosari
are predicted to be highly cost-effective (< $1700/DALY)
while many rural areas are less favourable. We even pre-
dict some of these towns in Yogyakarta SAR to be more
cost-effective than Yogyakarta City; however, this result
occurs only because we assume that the core resources
(e.g. laboratory and rearing facilities) that have already
been paid for and developed for the existing Wolbachia
programme in Yogyakarta City can be reused for the
surrounding areas in Yogyakarta SAR.
When the health sector and societal costs of averted
cases are deducted from the original programme invest-
ment, Wolbachia becomes a cost-saving intervention in
cities and a highly cost-effective intervention elsewhere
(Table 3 and Fig. 4a). One dollar invested in Wolbachia
can return between $1.35 and $3.40 (95UI $0.17–$9.67)
in medical and societal benefits depending on where the
programme takes place (Fig. 4a). In Jakarta, the medical
benefits alone are predicted to outweigh the cost of in-
vestment in Wolbachia (Fig. 4a).
Sensitivity and uncertainty
Our prediction that Wolbachia is cost saving is robust to
a reasonable range of parameter values (Fig. 4b). In a uni-
variate sensitivity analysis of the 2.5 and 97.5 percentiles
of the true parameter value, only a low value of the base-
line burden of dengue is sufficient to prevent Wolbachia
from becoming cost saving, and even then, the
Table 2 Predicted per year benefits of Wolbachia programmes in four sites. Only eligible areas (at least 1000 people per km2)
receive treatment. All costs are in 2018 US dollars and are not discounted. Figures in brackets represent 95% uncertainty intervals
Committed area Scale-up scenario
Yogyakarta City Remaining Yogyakarta
SAR
Jakarta Bali
Baseline cases per year (area wide) 14,488 (2955–47,
858)
93,604 (21,527–249,843) 444,528 (97,542–1,189,
217)
117,840 (27,862–324,
114)
Post Wolbachia cases per year (area wide) 722 (0–30,140) 36,674 (6805–180,567) 127,712 (0–749,850) 62,033 (9810–237,984)
Area-wide percent reduction (%) 94.4 (36.5–100) 59.1 (25.6–69.6) 65.7 (36.7–100) 52.4 (24.2–66.9)
Percent reduction within treated areas 94.4 (36.5–100) 87.2 (37.2–100) 65.7 (36.7–100) 82.8 (37.3–100)
Averted medical costs per year (millions
USD)
0.46 (0.14–1.19) 2.16 (0.67–4.70) 12.91 (4.49–25.08) 2.58 (0.82–5.11)
Averted societal costs per year (millions
USD)
0.52 (0.21–0.98) 2.36 (1.05–4.28) 14.17 (6.09–24.27) 2.77 (1.23–4.74)
Table 3 Predicted cost-effectiveness of Wolbachia at the end of the programme. Accelerated and sequenced programmes
correspond to completing roll out in 3 and 10 years, respectively. Only eligible areas (at least 1000 people per km2) receive
treatment. All costs are in present value 2018 US dollars. All costs and benefits are discounted at a rate of 3% per annum. Net costs
include cost offsets for medical and societal benefits from averted cases. Figures in brackets represent 95% uncertainty intervals
Committed area Scale-up scenario
Yogyakarta City Remaining Yogyakarta SAR Jakarta Bali
Accelerated introduction
Gross $/DALY averted $ 1831 (892–4522) $ 2133 (1048–4953) $ 1566 (857–3244) $ 2996 (1599–6778)
Net $/DALY averted (including averted
medical and societal costs)
$ − 543 (− 1419–1976) $ - 242 (− 1275–2438) $ − 839 (− 1500–731) $ 671 (− 719–4219)
Sequenced introduction
Gross $/DALY averted $ 1519 (737–3732) $ 2168 (1064–5042) $ 1111 (611–2307) $ 2366 (1264–5379)
Net $/DALY averted (including health
sector and societal costs)
$ − 862 (− 1572–1185) $ − 210 (− 1258–2528) $ − 1280 (− 1772–− 207) $ 64 (− 1050–2834)
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programme is still highly cost-effective ($1652/DALY, se-
quenced programme in Yogyakarta City, societal perspec-
tive). Parameters for the cost of the programme, cost per
case, and efficacy of the intervention were less critical for
overall cost-effectiveness than baseline burden due to the
higher uncertainty in the true burden of dengue.
Programmes are even predicted to be cost saving if
substantial challenges occur during deployment. If only
50% coverage were reached in the target area, resistance
emerges after 5 years or released mosquitoes are initially
uncompetitive with wild-type mosquitoes, benefit-cost
ratios remain above 1 (Fig. 4c, societal perspective). Fur-
thermore, if these events do occur, cost-effectiveness of
the programme can still be recovered by addressing
these threats (Fig. 4c and Additional file 1, S1.5). As
Wolbachia programmes become more proven over time,
it is expected that relaxed surveillance (relying on pas-
sive disease monitoring), innovations, and economies of
scale will reduce the cost of deployment. These have the
potential to increase the benefit-cost ratio by as much as
47%, as long as they do not come at the expense of
avoiding to detect more damaging failures of the
programme (Fig. 4c).
Discussion
Here we use existing cost data to build a programmatic
model for wMel Wolbachia. By applying this model in
Indonesia, we show that this novel technology can be an
economically advantageous intervention for dengue con-
trol and predict under what circumstances it might be
most cost-effective. Cost-effectiveness of Wolbachia is
predicted to be most favourable in dense cities where a
high concentration of people and dengue incidence
allow the high investment costs of Wolbachia to be
quickly offset. In such areas, programmes can become
cost saving, or dominant over existing practices, with
each $1 invested in a Wolbachia programme repaying
$1.35–$3.40 in averted medical and society costs of ill-
ness. Finally, we show that Wolbachia can also be cost-
effective in suburban and rural areas, particularly if they
can utilise programme infrastructure from nearby urban
areas. This is particularly relevant for the existing Wol-
bachia programme in Yogyakarta City and suggests that
expansion to nearby areas in Sleman and Bantul in
Yogyakarta SAR should be considered.
Assessing the cost-effectiveness of novel rear and re-
lease vector control strategies is important because of
Fig. 3 Maps of the gross cost-effectiveness of accelerated Wolbachia releases in Yogyakarta City (a), Yogyakarta SAR (b), Jakarta (c), and Bali (d).
Cost-effectiveness is measured in present value 2018 USD per disability-adjusted life year (DALY) averted with green areas being most favourable.
Select areas of interest and the national orientation of these sites (e) are shown for reference; more detailed background maps are available in
Additional file 1, S1.6. Site A falls within site B and is marked in a red outline
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their high upfront costs but potentially long-term bene-
fits. This makes the cost-effectiveness dynamics of wMel
Wolbachia more similar to mass vaccination than con-
ventional vector control. Like vaccination, this makes
cost-effectiveness of Wolbachia sensitive to the time
horizon of the evaluation. wMel Wolbachia has been ro-
bustly established in Cairns, Australia, since early 2011
[35], hence our assumed 10-year benefit time horizon.
More research is required to understand the sustainabil-
ity of Wolbachia replacement in dengue-endemic coun-
tries with more complex Aedes population genetics and
higher virus and mosquito importation rates from out-
side areas [39].
A number of previous studies have attempted to esti-
mate the cost-effectiveness of vector control interven-
tions for dengue [23, 40–43]. The methods used tend to
fall into one of two approaches: field trials or model-
based assessments. Experimental and observational con-
trol trials have been used to estimate cost-effectiveness
(per DALY averted) for larvicides in Cambodia ($313)
[40], community clear up campaigns ($3953) and ultra-
low volume spraying ($4472) in Mexico [42], and an in-
tegrated package of vector control interventions in Sri
Lanka ($98) [43]. Short-term control trials with disease
endpoints are likely to overestimate effectiveness due to
the effects of heard immunity and may mean interven-
tions delay rather than avert disease.
In response to this, model-based cost-effectiveness
evaluations can be used to give a more accurate estimate
of long-term effectiveness of a particular intervention.
However, because long-term effectiveness is not easily
measurable, such modelling studies often have to assume
a range of plausible efficacies with variable theoretical
support. Modelling studies have suggested larval control
($615–1267/DALY) [41], and more generic packages of
vector control ($679–1907/DALY) [23] can also be cost-
effective depending on true effectiveness. Finally, several
models have predicted the cost-effectiveness of dengue
vaccines [25, 44]. The cost-effectiveness of WHO’s rec-
ommended test-and-vaccinate strategy in Indonesia in
2015 was 0.8 to 0.6 times the per capita GDP (i.e. $2700
and $2000) if dengue seroprevalence rates at age 9 were
50% and 70%, respectively [25]. Despite vaccination hav-
ing a less favourable predicted cost-effectiveness than
Wolbachia, it is likely both vaccine and vector control
will be necessary to achieve control in the highest trans-
mission areas. Further work is needed to understand
how the economics of combinations of interventions
vary across transmission strata.
Given that Wolbachia is also not predicted to fully
eliminate dengue virus transmission in highly endemic
settings [19, 20] and given that many countries already
have established dengue control programmes, there is a
pressing need to understand how Wolbachia interacts
with other types of vector control and how the optimal
package of interventions may change in different envi-
ronments. Modelling and mapping techniques are crit-
ical for such investigations due to the impracticality of
conducting field trials among the many combinations of
different interventions [45, 46].
Our approach to assessing the cost-effectiveness of
Wolbachia combines the best currently available
Fig. 4 Benefit-cost ratios and their sensitivity. a The predicted benefit-
cost ratios of a sequenced release programme in each site
disaggregated by the type of benefit. A benefit-cost ratio of 1.0 or
higher indicates cost saving. b Sensitivity of cost-effectiveness of a
sequenced release in Yogyakarta City if the 2.5% value (orange) or
97.5% value (green) were used as opposed to the median value for
selected parameters. Net cost-effectiveness is in 2018 present-day
value USD per disability-adjusted life year averted and includes offsets
from health sector and societal perspectives. c Sensitivity of benefit-
cost ratios (BCRs) to future challenges or changes to a sequenced
release in Yogyakarta City. Green dots show potential cost-saving
measures, red dots unaddressed challenges to the programme, and
yellow dots addressed challenges to the programme. Dots above the
BCR = 1.0 line are cost saving from the societal perspective
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evidence for the effect of Wolbachia on transmission
[29] with a long-term mathematical model [19] to over-
come limitations of both of these approaches. This work
aims to provide an evidence-based first estimate that
gives quantitative support behind the decision to invest
large sums of money in an intervention that is likely to
have deferred but substantial benefits. Using model-
based estimates of the true case and economic burden of
dengue [19, 34] in Indonesia was a critical step in our
approach. Using reported case data would have signifi-
cantly underestimated the cost-effectiveness of Wolba-
chia, and more research is needed to understand, adjust
for, and ultimately fill gaps in disease surveillance [47].
This analysis was subject to a number of limitations.
First, our model did not consider logistical constraints
that may exist in releasing Wolbachia-infected mosqui-
toes at this scale. The largest current planned releases of
Wolbachia mosquitoes are in Medellin Colombia where
a sequenced programme will cover a combined 1.7 mil-
lion people over 151 km2. Reaching high coverage of
Wolbachia for Jakarta’s 11 million residents and 764-
km2 land area, particularly over a 3-year accelerated
campaign, may not be logistically feasible. New ap-
proaches to large-scale community engagement and re-
cruitment of release teams need to be developed. There
may also be constraints on the portability of assets, such
as centralised distribution of mosquitoes or laboratory
testing, across areas as wide as Bali that we did not con-
sider. Second, cost data for existing Wolbachia releases
were based on budgeted costs; actual costs may differ by
the end of the programme. Third, our analysis only in-
cluded the effects of Wolbachia on dengue, despite
showing strong protective effects against a range of
other arboviral diseases [3–5]. Given chikungunya is also
ubiquitous in Indonesia [48], our predictions may under-
estimate the cost-effectiveness of Wolbachia. Fourth, we
may underrepresent sub-national heterogeneity in the
costs of dengue cases and in the cost of a Wolbachia
programme. While both of these variables were in-
formed by other data from different countries and were
reasonably extrapolated across Indonesia using geospa-
tial mapping approaches, our Indonesian data from both
parameters came only from Yogyakarta city, the capital
of a region with a per capita GDP 39% below the Indo-
nesian average. More data on cost of illness and cost of
the intervention in other parts of Indonesia would
strengthen the case for national decision-making [49].
Finally, it should be mentioned that the cost-
effectiveness analysis presented here is intended to form
one part of the wider evidence base on whether or where
Wolbachia should be scaled up. To date, successful Wol-
bachia programmes have been underpinned by sustained
and robust engagement with both the community and
local stakeholders [14, 50]. In this analysis, we make
clear assumptions about the success of establishing Wol-
bachia in a target area, but clearly an assessment of
feasibility of this aim is a necessary precursor to assess-
ments of cost-effectiveness.
The biggest strength of our analysis is the use of com-
prehensive, detailed spatiotemporal models that incorp-
orate the latest projections of dengue case and economic
burden, and the likely impact Wolbachia could have
when deployed at scale. Given Wolbachia is an early-
stage novel intervention, we have also endeavoured to
include the broad range of uncertainty that exists in each
of these inputs and assess their impact overall cost-
effectiveness. Such comparisons are important if the
high upfront investment costs of Wolbachia are to be
justified, and these results can be used as part of the evi-
dence base in the decision to accelerate scale-up of Wol-
bachia to address the growing needs of arboviral
control.
Conclusions
In conclusion, in this study, we show that Wolbachia
has the potential to be a highly cost-effective and even
cost-saving intervention, especially if targeted to high-
density cities where the burden of dengue is concen-
trated. These findings are largely robust to uncertainties
in the long-term performance of Wolbachia, but further
longitudinal field data with epidemiological outcome
measures are required to validate these predictions and
assess how cost-effectiveness changes when combined
with other vector control interventions and vaccines.
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